Our Pipeline

Leading Innovations in Small Molecule Bioconversion

Our Pipeline of First-in-Class Bioconversion Medicines

Our pipeline is focused on converting large molecule therapeutics into small molecule drugs in high-impact therapeutic areas. Our lead programs target critical diseases across immunology, oncology, and metabolic disorders to bring enhanced accessibility, potency, and safety to patients.

Development Stage

Program

Target

Disease
Indication (s)

Discovery

Lead
Optimization

IND-
Enabling

Clinical
Trials

BFM-XXX

BFM-XXX

BMF-XXX

Undisclosed

xxx

CD38

CD20

Multiple

Crohn's Disease
Multiple Sclerosis

Multiple Myeloma

Multiple Myeloma

Target Selection Strategy

Bifrost Medicines focuses on high-demand, large-molecule drugs with established markets to reduce risks and enhance therapeutic safety and patient outcomes.

Safety and Efficacy Potential

Efficient Development Pathways

Proven Market Demand

8e855480-0227-4596-b0e2-44680e63722a (1).png

Key Therapeutic Areas

Target chronic conditions like multiple sclerosis and Crohn's disease

Immunology & Inflammation

Focused on immuno-oncology for cancer treatment improvements

Oncology

Addressing diabetes and cardiovascular disease's with potential treatments